文献速递主动脉疾病

国际多中心研究:广泛主动脉瘤患者全腔内主动脉修复的结局

Outcomes of Total Endovascular Repair of Aortic Arch and Thoraco-abdominal Aortic Aneurysms in the International Multicenter Aortic Research Group in a Selected Group of Patients with Extensive Aortic Aneurysm Disease.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2026-10-23

该回顾性多中心研究分析了2014至2024年间16个中心98例接受全腔内主动脉修复(TEAR)的广泛主动脉瘤患者,采用分期aBEVAR后TAAA FBEVAR方案。95例(97%)完成两阶段,主动脉相关死亡低,但卒中和脊髓缺血仍显著。

要点

  • 分期全腔内修复(aBEVAR后TAAA FBEVAR)主动脉相关死亡率低
  • 卒中/TIA发生率为13%,脊髓缺血为17%,需谨慎权衡
  • 3年生存率79±5%,再干预累积发生率31±6%

核心结论

  • 分期全腔内修复(aBEVAR后TAAA FBEVAR)与较低的主动脉相关死亡、再干预及目标动脉不稳定相关。
  • 卒中和脊髓缺血仍是显著并发症,需在患者选择和治療中仔细权衡。

研究设计与样本

  • 回顾性分析国际多中心主动脉研究组16个中心2014至2024年数据。
  • 纳入98例计划接受全腔内主动脉修复(TEAR)的患者,95例(97%)完成两阶段手术。
  • 46例(48%)为慢性夹层后动脉瘤,49例(52%)为退行性动脉瘤。
  • 所有患者采用分期aBEVAR后TAAA FBEVAR方案,两阶段中位间隔11个月(IQR 5,14)。

主要发现

  • 16例(17%)发生脊髓缺血(aBEVAR 2例,TAAA FBEVAR 14例),其中3例(3%)截瘫。
  • 67例(71%)有1年随访,其中6例(9%)目标动脉不稳定,5例(7%)新发心血管事件。
  • 中位随访32个月(IQR 3,61),估计3年生存率79±5%,再干预累积发生率31±6%。

临床怎么用

  • 对于广泛主动脉瘤患者,可考虑分期全腔内修复(aBEVAR后TAAA FBEVAR)以降低主动脉相关死亡。
  • 术前应充分评估卒中与脊髓缺血风险,并制定相应预防策略。

局限性

  • 回顾性研究设计。
  • 样本量相对较小(98例)。
  • 仅67例(71%)有1年随访数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to report outcomes of total endovascular aortic repair (TEAR) using arch branched endovascular aortic repair (aBEVAR) and thoraco-abdominal aortic aneurysm (TAAA) fenestrated branched endovascular aortic repair (FBEVAR). METHODS: Clinical data from 16 participating centres in the International Multicenter Aortic Research Group from 2014 to 2024 were retrospectively analysed. All patients who underwent TEAR were included. The primary outcome was aortic related mortality (ARM). Secondary outcomes included stroke and or transient ischaemic attack (TIA), spinal cord ischaemia (SCI), and freedom from target artery (TA) instability, re-interventions, and new cardiovascular events (CVEs) within 1 year. RESULTS: Of 98 patients scheduled for TEAR, 95 (97%) completed both stages, including 46 (48%) with chronic post-dissection aneurysms and 49 (52%) with degenerative aneurysms. A multistage approach with aBEVAR followed by TAAA FBEVAR was used in all patients, with a median interval between stages of 11 months (interquartile range [IQR] 5, 14). One (1%) rupture occurred between the staged procedures (successfully managed with off the shelf TAAA multibranch stent graft). Custom made and off the shelf TAAA FBEVAR devices were used in 79 (83%) and 16 (17%) patients, respectively. There were 12 (13%) stroke and or TIAs (aBEVAR, ten; TAAA FBEVAR, two); five (5%) had a modified Rankin Scale score > 3. Sixteen patients (17%) experienced SCI (aBEVAR, two; TAAA FBEVAR, 14) with three cases (3%) of paraplegia. Four patients (4%) died within thirty days; these were the only cases of ARM. Median follow up was 32 months (IQR 3, 61). Of 67 patients (71%) with available one year follow up, there were six (9%) with TA instability and five (7%) CVEs. Estimated three year survival was 79 ± 5% with a cumulative incidence of re-intervention of 31 ± 6%. CONCLUSION: Multistage TEAR with aBEVAR followed by TAAA FBEVAR was associated with low ARM, re-intervention, and TA instability. Stroke and SCI remain significant and must be carefully weighed during patient selection and treatment.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Gallitto E, Oderich GS, Kölbel T, et al. Outcomes of Total Endovascular Repair of Aortic Arch and Thoraco-abdominal Aortic Aneurysms in the International Multicenter Aortic Research Group in a Selected Group of Patients with Extensive Aortic Aneurysm Disease. Eur J Vasc Endovasc Surg. 2026. PMID: 42918390. doi:10.1016/j.ejvs.2026.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。